Mark Chin - 07 Oct 2021 Form 3 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Mark Chin
Issuer symbol
PYXS
Transactions as of
07 Oct 2021
Transactions value $
$0
Form type
3
Filing time
07 Oct 2021, 20:56:34 UTC
Previous filing
28 Jul 2021
Next filing
15 Oct 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PYXS Series B Convertible Preferred Stock 07 Oct 2021 Common Stock 1,433,261 See footnote F1, F2
holding PYXS Stock Option (Right to buy) 07 Oct 2021 Common Stock 15,725 $8.71 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each 6.359 shares of Series B Convertible Preferred Stock are currently convertible into one share of Common Stock at the option of the holder, for no additional consideration, and will convert automatically upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). These shares have no expiration date.
F2 These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.
F3 These stock options vest in three, substantially-equal annual installments beginning on the first anniversary of the August 19, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney